• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxart, Inc. - Common Stock (NQ:VXRT)

0.3200 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
April 27, 2022
Wednesday's session saw 784 companies set new 52-week lows. 
Via Benzinga
News headline image
3 Stocks That Have Analysts Running for the Exit ↗
April 27, 2022
These are the three stocks analysts hate and avoid now because they could see significant declines in the coming months. 
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
News headline image
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 29, 2022
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Recap: Vaxart Q4 Earnings ↗
February 24, 2022
Vaxart (NASDAQ:VXRT) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Vaxart... 
Via Benzinga
News headline image
Vaxart Stock Crosses 2 Key Levels Friday: What's Next? ↗
December 17, 2021
Vaxart Inc. (NASDAQ:VXRT) shares were trading higher ... 
Via Benzinga
News headline image
Vaxart Stock Breaks Out Of Pennant Pattern: Now What? ↗
November 29, 2021
Vaxart Inc. (NASDAQ:VXRT) shares were trading higher ... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
April 25, 2022
On Monday, 721 companies achieved new lows for the year. 
Via Benzinga
News headline image
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart ↗
February 17, 2022
Macy's Inc (NYSE:M) retail stores have something for everyo... 
Via Benzinga
News headline image
Why Vaxart Stock Is About Ready To See A Breakout ↗
November 24, 2021
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Wednes... 
Via Benzinga
News headline image
Vaxart Stock Is Being Squeezed At The End Of A Pattern ↗
November 18, 2021
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Thursd... 
Via Benzinga
News headline image
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger ↗
January 10, 2022
VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022? 
Via InvestorPlace
News headline image
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street ↗
December 29, 2021
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
News headline image
Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine ↗
December 21, 2021
As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem. 
Via InvestorPlace
News headline image
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron ↗
December 16, 2021
Vaxart Inc (NASDAQ: VXRT) plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two different... 
Via Benzinga
News headline image
VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down ↗
December 01, 2021
Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. 
Via InvestorPlace
News headline image
Cramer Gives His Opinion On Nokia, Delta Air Lines And More ↗
December 01, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DigitalOcean Holdings, Inc. (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021 ↗
November 02, 2021
Upgrades UBS upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
News headline image
Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance ↗
October 20, 2021
Vaxart stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative. 
Via InvestorPlace
News headline image
Can This COVID Vaccine Stock Help Make You Rich? ↗
October 16, 2021
This biotech has a nifty trick potentially up its sleeve. 
Via The Motley Fool
News headline image
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up ↗
October 12, 2021
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesd... 
Via Benzinga
News headline image
NASDAQ:VLDR Shareholder Notice: Update in Lawsuit Against Velodyne Lidar, Inc. ↗
October 12, 2021
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Velodyne Lidar, Inc. (NASDAQ:VLDR). 
Via SBWire
Topics Lawsuit
News headline image
NASDAQ:VXRT Investor Alert: Update in Lawsuit Against Vaxart, Inc. ↗
October 12, 2021
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Vaxart, Inc. (NASDAQ:VXRT). 
Via SBWire
Topics Lawsuit
News headline image
Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late? ↗
October 10, 2021
The company is working on a vaccine candidate that doesn't involve a needle. 
Via The Motley Fool
News headline image
Why Vaxart Shares Are Trading Higher Today ↗
October 08, 2021
Vaxart Inc (NASDAQ: VXRT) is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational... 
Via Benzinga
News headline image
18 Stocks Moving in Friday's Pre-Market Session ↗
October 08, 2021
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
News headline image
Why Vaxart Shares Are Surging In Thursday's After-Hours Session ↗
October 07, 2021
Vaxart Inc (NASDAQ: VXRT) is surging higher in after-hours trading Thursday after the company reported a Duke University-led study published in bioRxiv showed that the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
October 07, 2021
Gainers Vaxart (NASDAQ:VXRT) shares incr... 
Via Benzinga
News headline image
Why Vaxart Stock Tumbled in September ↗
October 07, 2021
A COVID-19 antiviral pill may undermine the biotech's value proposition. 
Via The Motley Fool
News headline image
Vaxart Starts Recruitment In Mid-Stage COVID-19 Oral Vaccine Trial ↗
October 06, 2021
Vaxart Inc (NASDAQ: VXRT) has begun recruiting subjects for its Phase 2 COVID-19 oral tablet vaccine clinical trial. Related: FDA Clears Vaxart's... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap